GH Research PLC (GHRS) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of GH Research PLC and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GHRS
GH Research PLC
$21.36HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.50HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — GHRS vs RARE
growth of $100 · dividends reinvested · last 5yGHRS +15.2% (+2.9%/yr)RARE -84.7% (-31.3%/yr)GHRS compounded faster over this window
Log scale — wide-divergence pair
GHRS RARE
GHRS vs RARE: by the numbers
- •GHRS is the larger company ($1.46B vs $1.43B market cap).
- •Both run net losses; GHRS's is the smaller (0.00% vs -81.79% net margin).
Metrics side by side
Valuation
| Metric | GHRS | RARE |
|---|---|---|
| P/S ratio | N/A | 1.99 |
| P/B ratio | 4.07 | N/A |
Profitability
| Metric | GHRS | RARE |
|---|---|---|
| Gross margin | 0.00% | 83.12% |
| Operating margin | 0.00% | -73.77% |
| Net margin | 0.00% | -81.79% |
| ROE | -17.32% | N/A |
| ROIC | -19.87% | -53.48% |
Growth (annualized)
| Metric | GHRS | RARE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 14.81% |
| Total return CAGR (5Y) | 0.52% | -30.14% |
Frequently asked
- How have GHRS and RARE total returns compared?
- Over the past 5 years, GHRS delivered 0.52% and RARE delivered -30.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.